Search

TransMedics Group Inc

Lezárt

SzektorEgészségügy

71.97 -0.04

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

70.27

Maximum

73.43

Fő mutatók

By Trading Economics

Bevétel

7.4M

15M

Értékesítés

16M

190M

P/E

Szektor átlag

18.359

49.241

Egy részvényre jutó nyereség

0.44

Profit margin

7.729

Munkavállalók

898

EBITDA

9.4M

37M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+34.59% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-336M

2.5B

Előző nyitás

72.01

Előző zárás

71.97

TransMedics Group Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 22. 21:11 UTC

News

TransMedics Group Inc. will report its third-quarter financial results on November 5, 2026, after the market closes, with a conference call scheduled for 4:30 p.m. ET.

2026. okt. 21. 20:07 UTC

Transmedics Group Inc shares are declining sharply, reversing early gains and trading below their 20-day moving average amid ongoing weakness since Tuesday's close.

2026. okt. 20. 20:01 UTC

News

TransMedics Group Inc is positioned to benefit from the Trump administration's proposed kidney care plan aimed at enhancing competition and innovation in kidney treatment.

2026. okt. 16. 20:02 UTC

Transmedics Group Inc shares are declining, reversing a trend of higher daily closes that persisted since Thursday's close.

2026. okt. 15. 19:46 UTC

Social Media

Stifel projects Transmedics Group Inc. will report third-quarter revenue between $185 million and $190 million, exceeding the Street's estimate of $178 million.

2026. okt. 14. 20:07 UTC

Transmedics Group Inc shares fell sharply, closing significantly lower compared to Tuesday's close and reaching a low around midday.

2026. okt. 13. 20:02 UTC

News
Social Media

Canaccord Genuity maintains Buy rating on TransMedics Group Inc while lowering price target to $94.00, reflecting ongoing confidence in the company's prospects.

2026. okt. 9. 20:06 UTC

Transmedics Group Inc shares are declining, unable to sustain an early spike, and are currently positioned significantly below their 20-day moving average.

2026. okt. 8. 20:07 UTC

Transmedics Group Inc shares declined sharply on Thursday, finishing notably lower and remaining substantially below their 20-day moving average.

2026. okt. 7. 19:50 UTC

Social Media
News

TransMedics Group Inc. advanced after Barclays initiated coverage with an Overweight rating and a $120 price target, despite earlier pulling back from a session high.

2026. okt. 5. 20:06 UTC

News

Transmedics Group Inc shares rose following Piper Sandler's initiation of coverage with an "Overweight" rating and a $100 price target.

2026. okt. 2. 20:07 UTC

Transmedics Group Inc is gaining amid a broader market rally, driven by falling U.S. Treasury yields and improved investor sentiment since Thursday's close.

2026. okt. 1. 20:02 UTC

Transmedics Group Inc shares fell sharply, reversing a recent trend of higher daily closes amid a shift in the asset's performance.

2026. szept. 30. 19:15 UTC

Transmedics Group Inc shares fell after an early rise, currently trading below the 20-day moving average and near the lower end of its one-month range.

2026. szept. 29. 19:45 UTC

Transmedics Group Inc is trading higher, rebounding from an early dip, although it remains below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 25. 20:07 UTC

Social Media

Transmedics Group Inc. shares rose following Canada's first Organ Care System heart transplant, expected to boost donor heart availability by 40%.

2026. szept. 24. 20:07 UTC

Transmedics Group Inc shares fell sharply, continuing a downward trend from Wednesday and finishing significantly below its 20-day moving average.

2026. szept. 23. 20:07 UTC

News

Transmedics Group Inc shares fell amid a broader market decline, despite reaffirming 2026 revenue guidance of $737 million to $757 million.

2026. szept. 22. 19:15 UTC

News

Transmedics Group Inc. appointed Fernando Araujo as CFO and reaffirmed 2026 revenue guidance of $737M to $757M, with shares trading higher.

2026. szept. 21. 20:06 UTC

Social Media

Transmedics Group Inc is trading higher following validation from a federal agency and a $7.27M contract for liver recovery services from Veterans Integrated Service Network 4.

2026. szept. 18. 20:06 UTC

Transmedics Group Inc shares fell, closing below Thursday's level after fluctuating throughout the day, marking three consecutive sessions of lower closes.

2026. szept. 17. 20:07 UTC

Transmedics Group Inc shares fell Thursday, declining from Wednesday's close despite a brief earlier rebound, amid overall lower market performance.

2026. szept. 16. 20:10 UTC

Transmedics Group Inc shares fell modestly amid a broader market decline, stabilizing near the midpoint of its one-month range.

2026. szept. 15. 20:07 UTC

Social Media

TransMedics Group shares are rising following an insider purchase by Director David Weill at $81.63, amid positive social media discussions about the company.

2026. szept. 14. 20:03 UTC

TransMedics Group Inc shares are gaining during Monday's session, despite earlier pullbacks. Broader market volatility is influenced by rising crude oil prices and inflation concerns.

2026. szept. 11. 20:02 UTC

News
Event
Social Media

TransMedics Group Inc shares are lower following the announcement of a CFO transition. The company reaffirmed its 2026 revenue guidance of $737 million to $757 million.

2026. szept. 10. 20:06 UTC

Transmedics Group Inc shares are lower amid broader market pressure, reflecting ongoing concerns over rising Treasury yields and inflation. No specific company news was identified.

2026. szept. 9. 20:07 UTC

Social Media

Transmedics Group Inc shares are lower today, breaking a recent trend despite positive sentiment reported by Jefferies' Transplant Tracker earlier this month.

2026. szept. 8. 19:56 UTC

News
Social Media

Transmedics Group reported EPS of $0.44 but lowered its adjusted operating margin guidance, contributing to a decline in shares since Friday's close.

2026. szept. 4. 20:07 UTC

News

Transmedics Group reported Q2 EPS of $0.44, missing estimates. The company raised its 2026 revenue outlook, boosting investor sentiment and shares during Friday's session.

Társak összehasonlítása

Árváltozás

TransMedics Group Inc Előrejelzés

Célár

By TipRanks

34.59% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 97.444 USD  34.59%

Magas 122 USD

Alacsony 65 USD

11 Wall Street elemző 12 hónapos célárain alapulva a(z)TransMedics Group Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

11 ratings

7

Vétel

4

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat